We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

NIH Drug Development Strategy Gets First Candidate Through Valley Of Death

News

Executive Summary

AesRx and its potential treatment for sickle cell disease are acquired by Baxter International, a measure of validation for the NCATS model of de-risking product development for rare and neglected diseases.